NCT06646172 Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy
| NCT ID | NCT06646172 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Median Sternotomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-10-24 |
| Primary Completion | 2024-10-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2024-10-24 with a primary completion date of 2024-10-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In light of the ongoing controversy surrounding the efficacy of bupivacaine liposomes, our study was designed to investigate, for the first time, the differential postoperative analgesic effects between bupivacaine liposomes combined with bupivacaine hydrochloride and bupivacaine hydrochloride alone in transverse thoracic muscle plane block treatment. The aim is to provide evidence-based medical guidance for drug selection in regional block local anesthesia.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18-90 years; * ASA Class I \~ III; * Patients undergoing elective median sternotomy. Exclusion Criteria: * Emergency surgery; * Re-operation; * Coagulation dysfunction; * Preoperative left ventricular function was poor (ejection fraction \<35%); * Systemic infection or injection site infection; * Neuromuscular diseases; * Mental illness; * Dependence on psychotropic drugs; * Allergic to bupivacaine liposomes and bupivacaine; * Patients have participated in previous trials or have been determined by a surgeon or anesthesiologist to be unsuitable for randomization; * Failure to obtain written informed consent from the patient or his/her representative
Contact & Investigator
Mei Wei, M.D.
STUDY DIRECTOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06646172 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Median Sternotomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06646172 currently recruiting?
Yes, NCT06646172 is actively recruiting participants. Contact the research team at liutzh@126.com for enrollment information.
Where is the NCT06646172 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06646172 clinical trial?
NCT06646172 is sponsored by Tongji Hospital. The principal investigator is Mei Wei, M.D. at Tongji Hospital. The trial plans to enroll 38 participants.